Can acetate via FFA receptors contribute to the diabetogenic effect of statins?

Finn Olav Levy; Jan-Bjørn Osnes

doi:10.1007/s00210-023-02647-7

Can acetate via FFA receptors contribute to the diabetogenic effect of statins?

Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):1245-1248. doi: 10.1007/s00210-023-02647-7. Epub 2023 Aug 29.

Authors

Finn Olav Levy¹, Jan-Bjørn Osnes²

Affiliations

¹ Department of Pharmacology, Division of Laboratory Medicine, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, P.O. Box 1057 Blindern, N-0316, Oslo, Norway. f.o.levy@medisin.uio.no.
² Department of Pharmacology, Division of Laboratory Medicine, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Sognsvannsveien 20, P.O. Box 1057 Blindern, N-0316, Oslo, Norway.

Abstract

Despite the proven effects of statins in preventing cardiovascular disease, their diabetogenic effect has caused concern. The mechanism of this diabetogenic effect is unknown. We suggest a novel mechanism that may contribute to the diabetogenic effect of statins, through an effect of statins that has apparently escaped previous consideration. Briefly, by inhibiting HMG-CoA reductase, statins may cause accumulation of acetate, which through FFA2 and FFA3 stimulation may inhibit insulin secretion.

Keywords: Bempedoic acid; Cholesterol; Diabetes; HMG-CoA reductase inhibitors; Lipid-lowering agents; Side effect.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acetates / pharmacology
Cardiovascular Diseases* / prevention & control
Diabetes Mellitus*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / pharmacology
Insulin Secretion

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Acetates

Abstract

Publication types

MeSH terms

Substances

Grants and funding